Latest Cetuximab Stories
THOUSAND OAKS, Calif., Aug. 11 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced top-line results from a randomized Phase 3 trial evaluating VectibixÂ® (panitumumab) as a first-line treatment in patients with recurrent and/or metastatic squamous cell head and neck cancer.
Drugs such as everolimus that target the protein mTOR are used to treat several forms of cancer, but not all patients respond to the treatment.
QUEBEC CITY, June 29 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.
NEW YORK, June 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that abstract O-0017, entitled "Subset Analysis of 5-FU Refractory Patients from a Randomized Ph II Study of Perifosine + Capecitabine (P-CAP) vs.
BETHESDA, Md., June 29 /PRNewswire-FirstCall/ -- Micromet, Inc.
Data Reported at ASCO Confirm a Statistically Significant Improvement in Both Time to Tumor Progression and Overall Survival in the Perifosine + Capecitabine Arm Versus Placebo + Capecitabine Arm QUEBEC CITY, June 8 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.
NEW YORK, June 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
To the surprise of researchers at Mayo Clinic who led a national clinical trial, a targeted therapy that provides benefit to patients with metastatic colon cancer has failed to help patients with less advanced, stage III cancer.
ROCKVILLE, Md., June 2 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), today announced the publication of preclinical results for its clinical-stage Aurora A/angiogenic kinase inhibitor, ENMD-2076, in human colorectal cancer xenograft models.
RIDGEFIELD, Conn., May 20 /PRNewswire/ -- Boehringer Ingelheim will announce preliminary data in the areas of head and neck cancer and non-small cell lung cancer (NSCLC) for one of the company's investigational compounds, BIBW 2992.
- Small missiles, especially grape, canister, fragments of iron, and the like, when fired, as upon an enemy at close quarters.
- To fire mitraille at.